Ting‐Shi Su
Papers
2
Total Citations
43
H-Index
2
About
Dr. Ting-Shi Su is a leading radiation oncologist whose research focuses on advancing radiotherapy for hepatocellular carcinoma (HCC), particularly in complex cases involving portal vein tumor thrombosis (PVTT). His major contributions center on comparing the efficacy and safety of stereotactic body radiotherapy (SBRT) versus intensity-modulated radiotherapy (IMRT) for this challenging patient population. His seminal 2021 study, which has garnered 41 citations, demonstrates that SBRT offers superior local control and survival outcomes compared to IMRT, while maintaining a manageable toxicity profile. This work has significantly influenced clinical practice, providing evidence-based guidance for selecting optimal radiation techniques in HCC with PVTT—a condition historically associated with poor prognosis. Dr. Su's research addresses a critical gap in hepatobiliary oncology, offering hope for improved outcomes in patients with advanced liver cancer. His findings are widely cited in the field, underscoring their impact on both clinical decision-making and future trial design. Through rigorous comparative effectiveness research, Dr. Su continues to shape the landscape of liver cancer radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2